Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT + Atezolizumab + Bevacizumab in Advanced HCC
NCT05488522Phase 1Recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Sep 2022
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Abramson Cancer Center. Primary endpoint: Dose-Limiting Toxicities at 3 years. Started Sep 2022; status: recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05488522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05488522.